title: Serum rituximab levels and efficiency of B cell depletion: differences between patients with rheumatoid arthritis and systemic lupus erythematosus.
authors: Venkat
authors: V
authors: Reddy
authors: Sara
authors: S
authors: Croca
authors: Delia
authors: D
authors: Gerona
authors: Inmaculada
authors: I
authors: De La Torre
authors: David
authors: D
authors: Isenberg
authors: Vickie
authors: V
authors: McDonald
authors: Maria
authors: M
authors: Leandro
authors: Geraldine
authors: G
authors: Cambridge
mesh_terms: D000328:Adult; D000368:Aged; D058846:Antibodies, Monoclonal, Murine-Derived / Q000097:blood* / Q000627:therapeutic use; D018941:Antigens, CD19 / Q000187:drug effects / Q000276:immunology*; D001172:Arthritis, Rheumatoid / Q000175:diagnosis / Q000188:drug therapy* / Q000276:immunology; D001402:B-Lymphocytes / Q000187:drug effects* / Q000276:immunology; D015331:Cohort Studies; D004305:Dose-Response Relationship, Drug; D004797:Enzyme-Linked Immunosorbent Assay; D005260:Female; D006801:Humans; D008180:Lupus Erythematosus, Systemic / Q000175:diagnosis / Q000188:drug therapy* / Q000276:immunology; D018655:Lymphocyte Count; D008297:Male; D008875:Middle Aged; D011237:Predictive Value of Tests; D011379:Prognosis; D012189:Retrospective Studies; D000069283:Rituximab; D016896:Treatment Outcome
chemical_list: D058846:Antibodies, Monoclonal, Murine-Derived; D018941:Antigens, CD19; D000069283:Rituximab